Belite Bio’s IND for LBS-008 gets FDA approval for Phase 1 trial
Category: #health  By Mateen Dalal  Date: 2019-04-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Belite Bio’s IND for LBS-008 gets FDA approval for Phase 1 trial

Drug development company, Belite Bio’s Investigational New Drug application for LBS-008 (BPN-14967), developed to treat AMD and Stargardt disease, has reportedly been approved by the U.S. Food and Drug Administration. 

As per trusted sources, Belite Bio’s new drug is the first to graduate from the US National Institute of Health’s Blueprint Neurotherapeutics Network, which has invested toward LBS-008's discovery and development and will continue to offer support and investment until the conclusion of its Phase 1 clinical trial. 

Dr. Konstantin Petrukhin, Columbia University Medical Center’s Associate Professor of Ophthalmic Science and inventor of the technology stated that the commencement of the Phase 1 trial is a significant milestone for LBS-008, which was sponsored by the NIH Blueprint Program right from lead optimization to preclinical proof of concept. The drug is anticipated to bring hope to a lot of patients affected by incurable forms of macular degeneration, Dr. Petrukhin added.

Dr. Tom Lin, Chairman of Belite Bio, said in a statement that the company is thrilled to announce the start of Phase 1 clinical trial of LBS-008 in the US in conjunction with the NIH.

The current favorable regulatory view of its technology has encouraged the company, as well as the systematic analysis published by the UK National Institute for Health Research, recognizing reduction of RBP4 as the most lucrative treatments for dry AMD and Stargardt disease, added Dr. Lin.

The company plans to continue working closely with its collaborators until the next clinical and regulatory milestone, Dr. Lin said.

For the record, LBS-008 is a treatment dedicated to preventing toxin build up in the eye that leads to severe conditions like atrophic dry AMD and Stargardt disease. The drug development company Belite Bio owns exclusive global rights for LBS-008. The drug had received orphan drug designation (ODD) in the US & EU, and a rare pediatric disease designation from the FDA for treating patients with Stargardt disease, reported sources.  

Source Credits: https://www.biospace.com/article/releases/belite-bio-announces-fda-approval-of-investigational-new-drug-ind-for-phase-1-clinical-trial-of-lbs-008-to-treat-macular-degeneration-and-stargardt-disease/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...